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Strategies used to enhance liposome-mediated drug delivery in vivo include the enhancement of stability and circulation
time in the bloodstream, targeting to specific tissues or cells, and facilitation of intracytoplasmic delivery. pH-sensitive
liposomes have been developed to mediate the introduction of highly hydrophilic molecules or macromolecules into the
cytoplasm. These liposomes destabilize under acidic conditions found in the endocytotic pathway, and usually contain
phosphatidylethanolamine (PE) and titratable stabilizing amphiphiles. Formulations without PE have also been developed.
Encapsulated compounds are thought to be transported into the cytoplasm through destabilization of or fusion with the
endosome membrane. Incorporation of a low mole percentage of poly(ethylene glycol) (PEG)-conjugated lipids into pH-
sensitive liposomes confers prolonged circulation times to these liposomes, which are otherwise cleared rapidly. While the
incorporation of PEG–lipids reduces the pH-dependent release of encapsulated fluorescent markers in vitro, it does not hinder
the cytoplasmic delivery of the markers per cell-associated liposome. This suggests that intracellular delivery is not dictated
simply by the destabilization of the liposomes. Antibodies or ligands to cell surface receptors can be coupled to pH-sensitive or
sterically stabilized pH-sensitive liposomes for targeting. pH-sensitive liposomes have been used to deliver anticancer drugs,
antibiotics, antisense oligonucleotides, ribozymes, plasmids, proteins and peptides to cells in culture or in vivo.D 2004 Elsevier B.V. All rights reserved.Keywords: Liposomes; Phosphatidylethanolamine, cholesteryl hemisuccinate; Sterically stabilized liposomes; Poly(ethylene glycol); Prolonged
circulation; Endocytosis; Low pH compartment; Intracellular delivery; Neoplastic drugs; Gene delivery; Antisense oligonucleotides; Ribozymes
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The development of strategies to increase the ability
of liposomes tomediate intracellular delivery of biolog-
ically active molecules has been the subject of intensive
research activity. The application of such strategies
would result in liposomes that could constitute crucial
tools to improve the therapeutic efficiency of many
drugs that exert their effect at the intracellular level.
The inclusion of lipids with fusogenic properties
results in the formation of the so-called ‘‘fusogenic’’
or polymorphic liposomes, since these undergo a
phase transition under acidic conditions, either in
the absence or presence of biological membranes.
Such liposomes are able to interact and promote
fusion or destabilization of target membranes (either
at the level of the plasma or endosomal membrane)
and have been described to release efficiently the
encapsulated material into the cytoplasm.
pH-sensitive liposomes are stable at physiologi-
cal pH (pH 7.4) but undergo destabilization, and
acquire fusogenic properties under acidic conditions,
thus leading to the release of their aqueous con-
tents. The concept of pH-sensitive liposomes emerged
from the fact that certain enveloped viruses devel-
oped strategies to take advantage of the acidification
of the endosomal lumen to infect cells, as well as
from the observation that some pathological tissues
(tumors, inflamed and infected areas) exhibit an
acidic environment as compared to normal tissues
[1].
Different classes of pH-sensitive liposomes have
been proposed in the literature according to the mech-
anism triggering pH-sensitivity [1–3]. The most com-
monly recognized concept involves the combination of
phosphatidylethanolamine (PE) or its derivatives with
compounds containing an acidic group (e.g. carboxylicgroup) that act as a stabilizer at neutral pH [4–6]. More
recently, the use of novel pH-sensitive lipids, synthetic
fusogenic peptides/proteins either encapsulated [7,8] or
incorporated in the lipid bilayer [9–13], and associa-
tion of pH-sensitive polymers with liposomes [14–16]
have been reported.
It should be emphasized, however, that when con-
sidering intravenous administration, in order to reach
target cells (such as tumor cells) and mediate cytoplas-
mic delivery, liposomes need to be stable in biological
fluids and exhibit long circulation times. The use of
lipidswithhigh transition temperatures (distearoylphos-
phatidylcholine, DSPC; hydrogenated soy PC, HSPC),
and the incorporation of cholesterol (Chol) and lipid
conjugates such as phosphatidylethanolamine–poly
(ethylene glycol) (PE–PEG), have led to a significant
decrease of leakage of the encapsulated drugs during
circulationor in the extracellularmilieu.Moreover, such
lipids also reduce non-specific interactions between the
liposomes and serum proteins (opsonins), thus prevent-
ing liposome clearance by the cells of the reticuloendo-
thelial system(RES). In addition, theuseof liposomesof
adequate size (below 150 nm) can contribute to the
increase of the circulation time [17–19].2. Mechanisms of intracellular delivery mediated
by pH-sensitive liposomes containing
phosphatidylethanolamine
2.1. Biophysical properties underlying the pH-
sensitivity of liposomes
In contrast to the majority of the phospholipids, PE
presents a minimally hydrated and small headgroup
which occupies a lower volume as compared to the
respective hydrocarbon chains, exhibiting a cone
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stabilizing phospholipids), thus hampering the forma-
tion of a lamellar phase [20,21]. The cone shape of PE
molecules favors the establishment of strong intermo-
lecular interactions between the amine and phosphate
groups of the polar headgroups, justifying the strong
tendency of these molecules to acquire the inverted
hexagonal phase above the phase transition tempera-
ture (TH) (for DOPE the TH is 10 jC). Intercalation of
amphiphilic molecules containing a protonatable acid-
ic group (negatively charged at physiological pH)
among PE molecules favors electrostatic repulsion
and allows the formation of bilayer structures, leading
to liposome formation at physiological pH and tem-
perature [22,23]. This latter approach constitutes the
basis for the biophysical mechanisms underlying the
pH-sensitivity exhibited by PE-containing liposomes.
While at physiological pH stable liposomes are
formed, acidification triggers protonation of the car-
boxylic groups of the amphiphiles, reducing their
stabilizing effect and thus leading to liposomal desta-
bilization, since under these conditions PE molecules
revert into their inverted hexagonal phase [1,24].
The choice of the amphiphilic stabilizers as well as
its molar percentage with respect to the PE content are
imposed by the desired properties of the liposomes,
including the extent of cellular internalization, the
fusogenic ability, pH-sensitivity and stability in bio-
logical fluids. Such properties determine the liposome
efficacy to mediate cytoplasmic delivery of the en-
capsulated molecules [1,2,25].
2.2. Binding and cell internalization
It has been suggested that pH-sensitive liposomes
are internalized more efficiently than non-pH-sensi-
tive formulations [26,27]. This has been attributed to
the tendency of PE-containing liposomes to form
aggregates, due to the poor hydration of its head-
group, which can explain their high affinity to adhere
to cell membranes [25,28].
In an attempt to further improve their binding and
cellular internalization, different strategies have been
explored based on receptor-mediated targeting through
specific ligands coupled to the liposome surface. pH-
sensitive liposomes composed of DOPE/oleic acid
(OA) (4:2) or DOPE/OA/Chol (4:2:4) and targeted
by the anti-H-2Kk antibody, exhibited a higher efficacyin mediating cytoplasmic delivery of their aqueous
contents as compared to the same formulations lacking
the antibody [29–31]. These results demonstrate that:
(i) the extent of liposome internalization is a crucial
step in the process of intracellular delivery and (ii)
receptor-mediated endocytosis is more efficient than
non-specific endocytosis. Nevertheless, although non-
pH-sensitive immunoliposomes (containing PC in-
stead of DOPE) are internalized as extensively as
pH-sensitive immunoliposomes, their capacity to me-
diate cytoplasmic delivery of the encapsulated mole-
cules is significantly lower [32,33]. These observations
suggest that fusion or destabilization of liposomes
induced by acidification of the endosomal lumen
represents the most important stage in the process of
intracellular delivery.
Fig. 1 illustrates the main steps involved in the
internalization and intracellular delivery mediated by
pH-sensitive liposomes. Following binding to cells,
the liposomes are internalized through the endocytotic
pathway, with or without the involvement of clathrin-
coated vesicles. Independently of the internalization
process, liposomes will be retained in early endo-
somes, which mature into late endosomes. The poten-
tial of pH-sensitive liposomes lies in their ability to
undergo destabilization at this stage, thus preventing
their degradation at the lysosomal level, and conse-
quently increasing access to the cytosolic or nuclear
targets [28,34].
2.3. Destabilization of liposomes at the endosomal
level
Studies involving the incubation of cells with
lysosomotropic agents (e.g. ammonium chloride or
chloroquine, which prevent endosome acidification)
demonstrate that the efficacy of pH-sensitive lip-
osomes depends on the pH decrease upon endosome
maturation. Furthermore, kinetic studies have shown
that liposomes composed of DOPE/OA, DOPE/pal-
mitoylhomocysteine (PHC) or DOPE/dipalmitoylsuc-
cinylglycerol (DSPG) [35] or of DOPE/cholesteryl
hemisuccinate (CHEMS) [36] release their contents
into the cytoplasm over a period of time that ranges
from 5 to 15 min upon their incubation with the
cells, thus indicating that cytoplasmic delivery occurs
from early and late endosomes. However, the mo-
lecular mechanisms by which liposomes overcome
Fig. 1. Hypothetical mechanisms of internalization and intracellular delivery of pH-sensitive liposomes (adapted from Ref. [28]).
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to release their contents into the intracellular space
remain to be clarified. Three hypothetical mecha-
nisms have been proposed (Fig. 1): (a) destabiliza-
tion of pH-sensitive liposomes triggers the destabili-
zation of the endosomal membrane, most likely
through pore formation, leading to cytoplasmic de-
livery of their contents; (b) upon liposome destabi-
lization, the encapsulated molecules diffuse to the
cytoplasm through the endosomal membrane; and (c)
fusion between the liposome and the endosomal
membranes, leading to cytoplasmic delivery of their
contents [28,37]. The fusogenic properties of PE
associated with its tendency to form an inverted
hexagonal phase under certain conditions suggest
that hypotheses (a) and (c) are the most plausible.
It should be emphasized that the fusogenic prop-
erties of the liposomes do not always correlate with
their efficacy in mediating intracellular delivery. Al-
though aggregation, release of contents and lipid
intermixing are observed at low pH (5.0) with
DOPE/CHEMS liposomes, no intermixing of aqueous
contents takes place [38]. Nevertheless, these lip-
osomes are efficient in delivering their encapsulated
contents into cultured cells [27].
Independently of the involved mechanisms, the
efficacy of cytoplasmic delivery mediated by pH-sensitive liposomes is drastically reduced upon in-
crease of the molecular weight of the encapsulated
molecules. Studies performed with high molecular
weight proteins (e.g. DTA and BSA), demonstrate
that only 0.01–10% of the molecules are released into
the cytoplasm, in contrast to essentially 100% release
observed with low molecular weight fluorescent
probes (calcein) [27].
2.4. DOPE as a crucial component to promote
cytosolic delivery
The incorporation of PEG (2000)–distearoyl-phos-
phatidylethanolamine into the membrane of DOPE/
CHEMS (6:4 molar ratio) decreased significantly the
pH-dependent release of a charged water-soluble
fluorophore, calcein, from liposomes suspended in
either buffer or cell culture medium (Fig. 2A) [39].
Surprisingly, the efficacy of such PEG-grafted pH-
sensitive liposomes to promote intracellular delivery
of their aqueous contents upon incubation with dif-
ferentiated THP-1 cells remained unaltered (Fig. 2B),
as demonstrated by a flow cytometry assay involving
dual fluorescence labeling of the liposomes [39]. This
lack of correlation between data obtained from bio-
physical assays generally used to assess pH-sensitiv-
ity, and the efficiency of the liposomes to interact with
Fig. 2. (A) pH-sensitivity of DOPE-containing liposomes. Calcein-encapsulating liposomes were incubated for 10 min at 37 jC in MES-
buffered saline at different pH values. The fluorescence intensity of calcein was measured before and after the addition of Triton X-100. (B)
Efficacy of intracellular delivery mediated by different liposome formulations, using a flow cytometry-based assay. Liposomes encapsulating
calcein at a self-quenched concentration (80 mM) and containing 1 mol% rhodamine–PE in the membrane were incubated with differentiated
THP-1 cells and analyzed by flow cytometry. Mean rhodamine fluorescence values reflect the binding and uptake of liposomes, and the mean
calcein fluorescence indicates intracellular dequenching of the dye fluorescence. The calculated ratio of calcein to rhodamine fluorescence is
taken as a measure of the amount of aqueous marker released intracellularly per cell-associated liposome (reproduced with permission [39,41]).
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sensitive liposomes (both plain and sterically stabi-
lized) mediate intracellular delivery of their contents
are not simply dictated by the release of contents as a
result of the decrease of endosomal pH.
These results were confirmed by Hong et al. [40],
who showed that liposomes composed of DOPE,
DPSG and DSPE–PEG (up to 5%) are pH-sensitive,
plasma stable and have a long circulation time in the
blood. Furthermore, they are able to release anentrapped marker more rapidly in tumor tissue homo-
genates (where the pH is lower than normal healthy
tissues) in comparison with non-pH-sensitive DPPC/
Chol/DSPE–PEG liposomes.
We have investigated the mechanisms by which
pH-sensitive liposomes interact with cells and mediate
the intracellular delivery of their aqueous contents. In
contrast to what was observed for DOPE/CHEMS
liposomes, liposomes composed of DOPE/phosphati-
dylglycerol (PG), DOPE/phosphatidylserine (PS), or
S. Simo˜es et al. / Advanced Drug Delivery Reviews 56 (2004) 947–965952DOPE/PC did not exhibit any pH-sensitivity, even
when incubated under very acidic conditions (Fig.
2A). Surprisingly, however, DOPE-containing lipo-
somes, shown to be non-pH-sensitive by biophysical
assays, mediated cytoplasmic delivery of their con-
tents as efficiently as well known pH-sensitive for-
mulations (e.g. DOPE/CHEMS) (Fig. 2B). However,
among the different formulations studied, DOPE/
CHEMS liposomes were those with the highest extent
of cell association [41].
Overall, these findings suggest that the processes
underlying the intracellular efficacy of the different
DOPE-containing liposomes involve more complex
mechanisms than the mere decrease of the endosomal
pH. On the other hand, the combination of these
results with those reported previously [39] indicates
that the presence of DOPE is the crucial factor
determining the ability of such liposomes to undergo
destabilization upon acidification of the endosomes.
In fact, in those studies non-pH-sensitive liposomes
composed of DSPC/CHEMS/DSPE–PEG were the
only ones where a correlation between a lack of pH-
sensitivity in buffer and inability to mediate intracel-
lular delivery was observed.
In this context, it is interesting to note that
studies performed by Vidal and Hoekstra [42] on
fusion between endocytotic vesicles (isolated from
reticulocytes) and liposomes with different compo-
sitions showed that the presence of PE when
compared with other phospholipids, namely PC, is
crucial to the fusion process. This specific effect of
PE or DOPE to promote liposome–endosome inter-
actions can be explained by the low hydration of its
polar headgroup as compared to the significant
repulsive forces associated with the hydration layer
of PC or DSPC polar headgroups [26]. Therefore,
the presence of DOPE enhances the hydrophobicity
of the liposomal membrane, thus facilitating ener-
getically favorable interactions between lipid bilayers.
Furthermore, DOPE tends to assume an hexagonal
inverted phase (HII) leading to the formation of
non-lamellar structures [43]. This may constitute a
key element to trigger endosomal destabilization,
thus leading to cytoplasmic delivery of their con-
tents. This proposal partially explains our observa-
tions on the striking similarity of the efficacy of intra-
cellular delivery mediated by all DOPE-containing
formulations.Vidal and Hoekstra [42], have also demonstrated
that treatment of endocytotic vesicles with trypsin
strongly reduced their interaction with PE-containing
liposomes, thus providing evidence that endosome-
associated proteins play a major role in this process.
Based on these findings, these authors suggest that
such proteins may not only be involved in the
process of membrane fusion, but also promote lipo-
some aggregation, which favors their destabilization.
Assuming that this hypothesis can be extended to
liposome–endosome interactions at the lumenal sur-
face of endocytotic vesicles, it could justify the
disparity of results between the biophysical studies
(in buffer) and those involving cultured cells, in
terms of acidification-induced destabilization. Similar
conclusions were obtained in lipid mixing studies
involving pH-sensitive liposomes and human eryth-
rocyte ghosts, where a decrease in the extent of lipid
mixing was observed by cleaving the sialic acid
residues of the glycocalyx [27].
Results obtained from studies with agents that
interfere with the endocytotic pathway also contribut-
ed to a better understanding of the mechanisms
underlying liposome–cell interactions. The drastic
reduction of the efficacy of intracellular delivery
observed for all the formulations tested when their
internalization was inhibited (using a mixture of
antimycin A, sodium fluoride and sodium azide)
indicates that such liposomes utilize the endocytotic
pathway (either mediated by clathrin or non-clathrin
coated vesicles) to promote the intracellular release of
their contents. On the other hand, the strong inhibition
observed for the calcein/rhodamine fluorescence ratio
when the cells were treated with lysosomotropic
agents demonstrate clearly that acidification of the
endocytotic vesicles is crucial to the intracellular
delivery mediated by the liposomes [39,41].
It should be noted that, despite the similarity of the
efficacy of intracellular delivery evaluated in terms of
calcein release, observed among the different lip-
osomes tested, such findings cannot be extrapolated
directly to other types of encapsulated molecules,
particularly to those with high molecular weights
[27]. In addition, we have reported that the ability to
mediate intracellular delivery of molecules with re-
latively high molecular weight (e.g. antisense oli-
gonucleotides) is significantly higher for liposomes
composed of DOPE/CHEMS compared to other
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were shown not to be pH-sensitive in buffer (DOPE/
PG, DOPE/PS and DOPE/PC) were those that proved
to be less efficient in releasing large molecules into
the cytoplasm.3. Long-circulating DOPE-containing pH-sensitive
liposomes
A critical issue in the in vitro and in vivo use of
pH-sensitive liposomes relates to the possibility that
properties like stability, pH-sensitivity and cell affin-
ity may be changed as a consequence of their
interaction with components of biological fluids or
with cells [1]. Extensive destabilization of DOPE/OA
liposomes was observed upon their incubation with
90% human plasma at physiological pH [45]. Ex-
traction of OA from the liposomes by serum albumin
was considered to be responsible for this destabili-
zation process. Nevertheless, this effect was shown
to be dependent on the size of the liposomes, since
liposomes with an average size smaller than 200 nm
were more stable in serum than larger liposomes,
although the opposite was observed when phosphate
buffered saline (PBS) was substituted for serum.
According to Liu and Huang [45], this stabilizing
effect arises from the fact that the high membrane
curvature of the liposomes of small size may favor
protein incorporation, like apoprotein A1 of the high
density lipoproteins (HDL), to replace the extracted
OA. This increase in liposome stability is accompa-
nied, however, by a significant reduction in pH-
sensitivity, thus constituting a limitation for their
appropriate use in vivo.
Several different strategies aimed at improving the
biostability of pH-sensitive liposomes have been de-
scribed, including the incorporation of a third com-
ponent to confer stability to the lipid bilayer. Inclusion
of Chol in DOPE/OA liposome formulations resulted
in a significant increase in plasma stability, without
decreasing their pH-sensitivity [5]. The use of other
amphiphilic stabilizers that were shown to be resis-
tant to the extraction by albumin (such as Chol
derivatives—CHEMS, or lipids with double acyl
chains—DPSG) resulted in the formation of lipo-
somes exhibiting higher stability in biological fluids,
while maintaining their pH-sensitivity [25,46].In addition to the limitations related to stability and
changes in pH-sensitivity, the in vivo efficacy of pH-
sensitive liposomes depends strongly on the interac-
tions with serum components (opsonins) that influ-
ence their pharmacokinetics and biodistribution.
Although the number of studies describing the in vivo
use of pH-sensitive liposomes is scarce, the consensus
is that upon their intravenous administration these
liposomes are cleared rapidly from blood circulation,
accumulating in the liver and spleen [1,30,39,47]. On
the other hand, the tendency of pH-sensitive lipo-
somes to aggregate in the presence of biological fluids
may explain their accumulation in the lungs [30].
Despite the fact that pH-sensitive liposomes exhibit
a higher affinity to macrophages than non-pH-sensi-
tive liposomes [1], their pharmacokinetics and biodis-
tribution pattern are essentially the same [48]. In vivo
studies using pH-sensitive immunoliposomes (DOPE/
OA) demonstrated that the presence of an antibody at
the liposomal surface affects neither their pharmaco-
kinetics (namely the blood clearance rate) nor their
biodistribution [49].
Both properties, i.e. pH-sensitivity and prolonged
circulation time, are highly desirable for the delivery
of therapeutic macromolecules, such as nucleic acids,
to cells. pH-sensitive liposomes that can circulate in
the blood for long periods and deliver encapsulated
macromolecules to target cells may be useful in this
regard. In vivo studies using the ganglioside GM1
were shown to confer relatively prolonged residence
in circulation to pH-sensitive liposomes composed of
DOPE and DPSG [47].
The inclusion of lipids with covalently attached
PEG in liposomes of various (non-pH-sensitive)
compositions has been shown to overcome the prob-
lem of their rapid removal by the RES [50–53]. One
of the first compositions of liposomes with the
combined properties of pH-sensitivity and prolonged
circulation in vivo was developed in our laboratory
[39]. The blood clearance curve of 111In encapsulated
in sterically stabilized pH-sensitive liposomes (Fig.
3A) was similar to that of previously developed
liposomes with prolonged circulation time [54,55].
A substantial percentage of liposomes (8.5%)
remained in the blood after 24 h. In contrast, the
radioactive marker encapsulated in regular pH-sensi-
tive liposomes was almost completely eliminated
from the bloodstream within 0.5 h. The t1/2 of control
Fig. 3. Blood clearance curves of regular pH-sensitive, sterically stabilized pH-sensitive, and control sterically stabilized liposomes. 111In-loaded
liposomes (A) or liposomes containing lipid-associated 111In (B) were injected intravenously into rats. Blood samples were taken after various
times, and radioactivity was determined in a gamma counter (the first blood sample was drawn immediately after injection at time 0). Percent of
injected dose was calculated and plotted against time. E, DOPE/CHEMS (6:4) liposomes; ., DOPE/CHEMS/PE–PEG (6:4:0.3) liposomes;
n, DSPC/CHEMS/PE–PEG (6:4:0.3) liposomes (reproduced with permission [39]).
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stabilized pH-sensitive DOPE/CHEMS/PE–PEG lip-
osomes was similar (11.8F 0.7 and 11.1F 0.6 h,
respectively). The area under the curve for control
liposomes was greater than that for sterically stabi-
lized pH-sensitive liposomes (1071F151% and
629F 52% dose h/ml, respectively), presumably be-
cause a larger number of the latter was taken up
rapidly by the liver and spleen (Table 1 and Fig. 3A,
time = 0 point), and therefore did not appear in bloodsamples. It is important to note that the area under the
curve for regular pH-sensitive liposomes (6.47F
1.24% dose h/ml) was about 100-fold lower than
that for sterically stabilized pH-sensitive liposomes.
The radioactive marker encapsulated in the former
liposomes was eliminated from the circulation either
because it leaks out as a result of the interaction of
plasma proteins with liposomes, or due to phagocy-
tosis of the liposomes by the cells of the RES. To
discriminate between these possibilities we associated
Table 1
Tissue distribution of liposome-encapsulated [111In] 24 h after
intravenous injection in rats (adapted from [39])
Tissue Percent of injected 111In dose per g in tissues
DOPE/CHEMS DOPE/CHEMS/
PE–PEG
DSPC/CHEMS/
PE–PEG
Liver 5.46F 1.83 2.01F 0.23 0.76F 0.28
Spleen 4.15F 0.6 22.06F 2.68 6.27F 0.33
Heart 0.03F 0.02 0.16F 0.01 0.27F 0.08
Kidneys 0.12F 0.01 0.24F 0.03 0.33F 0.04
Lung 0.03F 0.01 0.17F 0.02 0.25F 0.01
Skin 0.01F 0 0.03F 0.01 0.05F 0.01
Bone 0.05F 0.02 0.53F 0.17 0.25F 0.03
Muscle 0.02F 0.01 0.02F 0 0.02F 0
Urine 2.22F 0.94 1.36F 0.28 1.89F 0.83
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clearance curves of lipid-labeled liposomes (Fig. 3B)
showed rapid elimination from the circulation of the
lipid component of the regular pH-sensitive lipo-
somes but not that of sterically stabilized pH-sensi-
tive liposomes. This observation indicates that the
elimination of the liposome-encapsulated water-solu-
ble marker, described above, was mostly due to
removal of the liposomes from the blood by the
RES.
111In encapsulated in either long circulating pH-
sensitive or control liposomes had similar patterns of
distribution in vivo in that it primarily accumulated in
the spleen and liver (Table 1). Injection of regular pH-
sensitive liposomes resulted in a high level of 111In in
the liver. This observation and the rapid clearance of
these liposomes from the circulation (Fig. 3) indicate
that most of the liposomes are taken up within an hour
by liver cells and that only a fraction of the encapsu-
lated marker leaks out and is then excreted in urine
(Table 1). Although 24 h after injection a higher
fraction of the DOPE/CHEMS/PE–PEG liposomes
was localized in the liver and especially in the spleen,
compared with the non-pH-sensitive control DSPC/
CHEMS/PE–PEG liposomes, the total urinary excre-
tion of 111In was also about 2-fold lower compared
with the control liposomes (Table 1). This result,
together with the observation that the t1/2 (and hence
the clearance rate) of both sterically stabilized lip-
osomes were similar, suggests that a higher fraction of
the contents of pH-sensitive liposomes was accumu-
lated and retained in the liver and spleen, most likely
because they were delivered into the cytoplasm andthus partially avoided the usual metabolic processing
of liposome contents.
In another approach, DOPE-containing liposomes
were stabilized in the bilayer form through the addition
of a cleavable lipid derivative of PEG in which the
polymer was attached to a lipid anchor via a disul-
fide linkage (PEGUSUSUDSPE) [56,57]. Lipo-
somes stabilized with either a non-cleavable PEG
(PEGUDSPE) or PEGUSUSUDSPE retained an en-
capsulated dye at pH 5.5. However, treatment at this
pH of liposomes stabilized with PEGUSUSUDSPE,
with either dithiothreitol or cell-free extracts, caused
contents release due to cleavage of the PEG chains and
concomitant destabilization of the DOPE liposomes.
Pharmacokinetic studies suggested that PEGUSU
SUDSPE was rapidly cleaved in circulation. In addi-
tion, therapeutic studies performed in a murine model
of B-cell lymphoma demonstrated clearly that the
developed pH-sensitive formulation targeted to the
CD19 receptor was superior to stable, long-circulating,
targeted non-pH-sensitive liposomes, despite the more
rapid drug release and clearance of the pH-sensitive
formulation [57].
Recently, a novel category of pH-sensitive lip-
osomes based on the incorporation of a PEG–diortho
ester–distearoyl glycerol conjugate (POD) has been
described [58]. This conjugate, composed of a head-
group, an acid-labile diortho ester linker and a hydro-
phobic tail was shown to be stable at neutral pH for
greater than 3 h, but degraded completed within 1 h at
pH 5. Liposomes composed of POD/DOPE (1:9)
remained stable for up to 12 h in neutral buffer and
in the presence of 75% fetal bovine serum (content
release less than 25%), releasing their contents (84%)
in the following 4 h. At pH 5–6, PEG headgroups are
cleaved off, leading to liposome aggregation and
release of most of their contents in 10–100 min.
According to the authors, the fast kinetics of acid-
catalyzed POD hydrolysis, gives these liposomes a
great potential for the rapid delivery of drugs/genes at
therapeutic sites where the decrease of pH is perhaps
only one unit pH or less. The blood clearance pattern
of these liposomes was monophasic, with an elimina-
tion half-life of 200 min, the liver and intestine being
the main sites of accumulation of these liposomes. It
remains to be seen whether the incorporation of other
lipids such as Chol is able to further improve the
blood half-life of these liposomes.
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liposomes composed of DOPE and Chol, together
with the positively charged lipid, didodecyldimeth-
lyammonium chloride (DODAC). The mixture was
stabilized in a bilayer organization by including PE–
PEG (30:45:15:10). The cationic lipid was included
to promote binding of the liposomes to the cells via
electrostatic interactions. The use of PE–PEG with
different acyl chains, leading to different exchange
rates of this component from the lipid bilayer, pro-
vides the liposomes a time-dependent destabilization.
Such a strategy was evaluated for the delivery of
mitoxantrone. It was observed that the decrease in the
length of the acyl chain of PE–PEG lipid (from DSPE
to dimyristoylphosphatidylethanolamine (DMPE))
correlates with an increasing rate of liposome clear-
ance from blood, as well as with an increasing drug
leakage rate. In the case of liposomes composed of
PEG–DMPE, almost 50% of the injected dose accu-
mulated in the liver at 1 h, with only a small increase at
later times, while for liposomes stabilized with PEG–
DPPE liver accumulation occurred at later times (be-
tween 1 and 4 h). Less than 15% of the injected dose of
PEG–DSPE-containing liposomes was observed in
the liver after 24 h [59].
The therapeutic activity of mitoxantrone-contain-
ing liposomes was tested either against a pseudome-
tastatic leukemia murine model (L1210) or a human
colon subcutaneous xenograft model (LS180). In the
former study, upon intravenous administration, lip-
osomes containing PEG–DMPE or PEG–DSPE
showed a higher therapeutic activity (most animals
showing disease-free survival) than the free drug or
mitoxantrone-containing DSPC/Chol liposomes. In-
terestingly, despite the different pharmacokinetic
properties referred to above, both fusogenic formula-
tions exhibited similar therapeutic activity. This can
be explained by the fact that in the leukemia model
tumor cells are localized in readily accessible organs
such as the liver and spleen [59].
In the treatment of distal (non-RES) tumor sites,
such as in the case of the subcutaneous LS180 model,
a different trend was observed. Liposomes containing
PEG–DSPE presented the highest activity among the
several treatments tested, while the ability of lip-
osomes containing PEG–DMPE to delay initiation
of tumor growth was even lower than that observed
for free drug. In this tumor model, the increasedtherapeutic activity is consistent with the use of a
fairly stable system that provides greater mitoxantrone
bioavailability and delivery [59].
More recently, the same approach was used for
both DNA and oligonucleotide delivery, except that
another exchangeable PEG conjugate (PEG–ceram-
ide) was incorporated into the lipid bilayer [60,61].4. Alternative strategies to generate liposomes that
are fusogenic under acidic conditions
Although the development of pH-sensitive lipo-
somes has been associated frequently with the incor-
poration of DOPE in the liposome formulation, other
strategies have also been explored.
4.1. The use of novel pH-sensitive lipids
Results obtained with a new type of pH-sensitive
liposome formulation, composed of egg yolk phos-
phatidylcholine (EPC) liposomes bearing succiny-
lated poly(glycidol), a PEG derivative having
carboxyl groups, showed that fusion ability of the
liposomes increases under weakly acidic and acidic
conditions [62]. This has been shown to result in
intensive and diffuse cytoplasmic fluorescence as a
consequence of intracellular delivery of calcein.
According to their observations, the authors con-
cluded that polymer-modified liposomes, upon en-
docytosis by CV-1 cells, transfer their content into
the cytoplasm by fusing with the endosomal mem-
brane [63]. This strategy has been utilized recently
to target anti-BCG antibody-bearing pH-sensitive
liposomes to tumor cells expressing BCG antigen
[16].
More recently, three different approaches have
been taken to generate pH-sensitive liposomes in
the absence of DOPE [64–66]. Formulations con-
sisting of cationic/anionic lipid combinations were
shown to be highly efficient vehicles for intracellular
drug and gene delivery. Liposomes composed of EPC,
dimethyldioctadecylammonium bromide (DDAB),
CHEMS, and Tween-80 (25:25:49:1, mol/mol) were
shown to stably entrap calcein at pH 7.4 and undergo
destabilization and irreversible aggregation under
acidic pH. Compared to pH-sensitive liposomes incor-
porating DOPE, these liposomes showed improved
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[65].
Another promising strategy consisted of preparing
anionic pH-sensitive liposomes composed of diolein/
CHEMS (6:4). The results show that these liposomes
are stable at physiological pH, but undergo rapid
aggregation and efficiently release encapsulated cal-
cein at pHV 5.0. Complexes formed upon association
of the developed liposomes with DNA–protamine
mixtures maintained their transfection activity in me-
dia containing up to 50% fetal bovine serum, in
contrast to what was observed for DOPE-containing
liposomes [64].
Promising results in terms of pH-sensitivity and
resistance to serum were also obtained using a novel
liposome formulation composed of PC, CHEMS,
oleyl alcohol (OAlc), and Tween-80 [66]. Compared
to DOPE-based pH-sensitive liposomes, the above
formulation showed much better retention of its pH-
sensitive properties in the presence of 10% serum.
4.2. Co-encapsulation of synthetic fusogenic peptides
and therapeutic molecules into liposomes
The liposomal co-encapsulation of therapeutic
molecules with peptides has turned out to be a
promising strategy to promote cytosolic delivery of
hydrophilic molecules with limited access to subcel-
lular compartments. Gelonin, a type I plant toxin,
constitutes an example of such a compound known to
inactivate ribosomes and arrest protein synthesis. The
inability of this compound to permeate the plasma
membrane and to escape efficiently from endosomes
into the cytosol, leads to its rapid degradation within
endosomes and lysosomes, thus compromising its
antitumor activity. In order to overcome this problem,
gelonin was co-encapsulated inside pH-sensitive lip-
osomes with listeriolysin O, the pore-forming protein
that mediates escape of the intracellular pathogen
Listeria monocytogenes from the endosome into the
cytosol [8]. Such a strategy resulted in a dramatic
improvement on the cytotoxicity of encapsulated
gelonin against the murine B16 melanoma cell line,
relative to free gelonin or gelonin encapsulated alone
in pH-sensitive liposomes. Interestingly, the inclusion
of PEG strongly decreased the cytotoxicity of the pH-
sensitive formulation co-encapsulating gelonin and
listeriolysin O. It remains to be seen whether theinclusion of PEG compromises the cell uptake and/
or the pH-sensitivity properties of the liposomes [8].
A similar strategy has been explored by Mastro-
battista et al. [7], who have demonstrated that co-
encapsulation of a pH-dependent fusogenic peptide
(diINF-7) and diphtheria toxin A chain (DTA) in non-
pH-sensitive immunoliposomes promotes cytosolic
delivery of the encapsulated macromolecule. This
peptide (resembling the NH2-terminal domain of in-
fluenza virus hemagglutinin HA-2 subunit) was used
because functional characterization studies showed its
ability to induce fusion between liposome membranes
and leakage of liposome-entrapped compounds when
exposed to low pH. Moreover, co-encapsulation of
diINF-7 into DTA-containing immunoliposomes re-
sulted in drastically increased cytotoxicity toward
ovarian carcinoma cells, indicating that this peptide
can be used to obtain cytosolic delivery of liposome-
entrapped drugs with poor membrane permeation
capacities [7].
4.3. Association of synthetic fusogenic peptides/
proteins with cationic liposomes
Since cationic liposome/DNA complexes are
thought to enter cells primarily via endocytosis, it
has been hypothesized that the use of peptides that can
destabilize endosomes or facilitate the fusion of the
liposome/DNA complexes with the endosomal mem-
brane would enhance gene delivery. Incubation of
COS-7 cells with a ß-gal-expressing plasmid, and
anionic or cationic derivatives of the N-terminal
peptide of the HA-2 subunit of the influenza virus
fusion protein, hemagglutinin, in the presence of
Lipofectin, resulted in the enhancement of transfec-
tion activity over that of Lipofectin alone, by a factor
of 2–7 [67]. The levels of Transfectam (lipopoly-
amine)-mediated transfection of H225 human mela-
noma cells could be increased by up to 1000-fold
(over that obtained with a sub-optimal charge-equiv-
alent (1.5) of Transfectam/DNA) by adding the hem-
agglutinin-derived peptide INF6 to the preformed
lipoplexes [68]. The association of the pH-sensitive
peptide GALA [69,70] with DOTAP/DOPE (1:1) lip-
osomes before complexation with plasmid DNA
resulted in a significant enhancement in luciferase
expression in COS-7 cells, which depended on the
cationic liposome/DNA (+/ ) charge ratio [71].
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destabilization due to their fusogenic properties may
also be extended to proteins. In fact, studies on the
mechanisms of gene delivery mediated by transferrin-
associated lipoplexes performed in our laboratory
have indicated that besides triggering internalization
of the complexes, transferrin may also play a role in
the cytoplasmic delivery of DNA by facilitating endo-
some destabilization [72]. In fact, transfection experi-
ments carried out with cells pre-treated with drugs that
prevent acidification of the endosomal lumen (bafilo-
mycin A1 and chloroquine) showed that a significant
inhibition was observed not only in the levels of
transfection activity, but also in the extent of release
of complexed DNA into the cytoplasm, as assessed by
fluorescence microscopy [P. Pires, S. Simo˜es, N.
Du¨zgu¨nes, M.C. Pedroso de Lima, unpublished data].
As opposed to the observation of diffuse cytoplasmic
fluorescence in the absence of the lysosomotropic
drugs, treatment of cells resulted in punctate fluores-
cence restricted to intracellular organelles, suggesting
that complexed DNA was unable to escape from
endosomes. Furthermore, recent studies on the kinet-
ics of the initial steps involved in lipoplex–cell
interactions have indicated that association of trans-
ferrin to lipoplexes increases the extent of fusion with
endosomes. Overall, these results reinforce the hy-
pothesis that transferrin acquires fusogenic properties
under acidic conditions via exposure of hydrophobic
domains, thus facilitating endosomal disruption and
intracellular release of DNA [72,73].
Alerted by these results and by earlier reports
describing the ability of albumin to promote mem-
brane fusion under acidic conditions [74,75], we
demonstrated that albumin could also function as a
fusogenic protein that destabilizes endosomes under
acidic conditions, thus enhancing intracellular gene
delivery and transfection activity [76].
4.4. Association of pH-sensitive polymers with
liposomes
Over the last few years, a number of studies from
Leroux and collaborators have demonstrated the po-
tential of alkylated N-isopropylacrylamide (NIPAM)
copolymers to confer pH-sensitivity to liposomes.
Complexation of hydrophobically-modified copoly-
mers of NIPAN (either randomly or terminally alky-lated) with EPC/Chol liposomes resulted in an
enhancement of in vitro release of both highly-water
soluble markers and amphipathic drugs upon acidifi-
cation [14,77,78]. Liposomes anchoring randomly-
alkylated NIPAM and containing ara-C were shown
to mediate a higher cytotoxicity towards J774 macro-
phage-like cells as compared to non-pH-sensitive lip-
osomes [78]. More recently, different NIPAM based
copolymers were synthesized and evaluated in terms
of their ability to confer pH-sensitivity and serum
stability [78–80] as well as steric stabilization to
liposomes [79,80].
Coating of liposomes with terminally alkylated
NIPAM copolymer promotes steric stabilization of
liposomes, thus leading to prolonged blood circula-
tion. Nevertheless, since this effect was still considered
insufficient for in vivo purposes, co-incorporation of
PEG–lipid derivatives into the liposomal surface was
assessed. As expected, a significant increase in blood
circulation time was observed, blood clearance profiles
being essentially similar to that observed for stealth
liposomes lacking NIPAM. Consistent with previous
observations, the stabilizing effect of PEG significant-
ly reduced the liposome pH-sensitivity conferred by
the copolymers [39,79].5. Applications of long circulating pH-sensitive
liposomes for the delivery of therapeutic molecules
The versatility of pH-sensitive liposomes has been
well illustrated in a wide range of applications. These
include: (a) the transport of fluorescent probes that
allowed not only to evaluate the efficacy of different
liposome compositions, but also to clarify the mech-
anisms involved in intracellular trafficking; (b) the
efficient delivery of neoplastic drugs or recombinant
proteins; (c) the intracellular transport of antigens,
aiming at clarifying the intracellular pathways in-
volved in processing and presentation of antigens as
well as at enhancing the immune response to tumor
cells; and (d) the intracellular transport of genetic
material for application in gene and antisense thera-
pies. Examples of applications of pH-sensitive lip-
osomes for the transport and intracellular delivery of
therapeutic agents are shown in Table 2.
To improve the therapeutic efficacy of drugs
entrapped in pH-sensitive liposomes, a large amount
Table 2
Therapeutic applications of pH-sensitive liposomes
Liposome formulation (composition
and method of preparation)
Encapsulated material Target disease/therapeutic
applications
Reference
Drugs
DOPE/DSPG/DSPE–PEG (7:3:5)
(reverse-phase evaporation)
Methotrexate Cancer therapy [40]
PC/DDAB/CHEMS/Tween-80/
folate–PE–PEG (25:25:49:1:0.1)
Cytosine-h-D-arabinofuranoside Cancer therapy (KB human
oral cancer cells)
[65,66]
PC/CHEMS/Tween-80/OAlc/folate–
PEG–Chol (50:50:2:80:0.5)
(freeze– thawing)
DOPE/CHEMS/PEGUSUSUDSPE/
MAL–PEG–DSPE[anti-CD19]
(6:4:0.12:0.06) (hydration method)
Doxorubicin Cancer therapy (hematological
malignancies, B-lymphoma)
[57]
DOPE/N-succinyl-DOPE (70:30) Gentamicin Intracellular infections [93]
DOPE/N-glutaryl-DOPE (70:30)
DOPE/N-succinyl DOPE/Chol/PEG–
ceramide (35:30:30:5)
(freeze– thawing)
[94]
DOPE/CHEMS Staurosporin Inflammatory processes
(endotoxin shock). Suppression
of tumor necrosis factor (TNF)
production
[95]
Antisense oligonucleotides
DOPE/CHEMS (6:4) Against the HIV-1 RRE (15-mer) Inhibition of HIV-1 replication
in macrophages
[44]
DOPE/CHEMS/PE–PEG(6:4:03)
(reverse-phase evaporation)
DOPE/OA/Chol (1:1.3:0.4)
(freeze– thawing)
Against the start codon AUC
of Env gene mRNA
of Friend retrovirus (15-mer)
Inhibition of the translation of
Env protein of Friend retrovirus
in cultured cells
[96–99]
DOPE/CHEMS (3:2) (freeze– thawing) Against sodium/myo-inositol
cotransporter mRNA
(20-mer)
Bipolar affective disorders
(inhibition of inositol uptake
in astrocytes)
[100]
DOPE/CHEMS (3:2) (freeze– thawing) FICT-labeled antisense
oligonucleotide
Cancer therapy (NG 108-15
neuroblastoma and glioma cells)
[101,102]
PE/CHEMS/Chol (7:4:2) (reverse-phase
evaporation)
32P-TJU-2755 against TNF-a
mRNA
Endotoxemia: immune reactions:
inflammatory diseases
[103]
Reporter genes
DOPE/N-citraconyl-DOPE/Chol/folate–
PEG–DOPE
(45.8:10:40:0.1)
pDTS h-gal condensed with
poly-L-lysine
Cancer therapy (transfection of
KB human oral cancer cells)
[87]
DDAB/CHEMS/folate–PE–PEG
(30:70:0.1) (freeze– thawing)
pCMV-Luc condensed with
poly-L-lysine
[64]
Diolein/CHEMS (6:4) (ethanol injection) pCMV-Luc condensed with
poly-L-lysine
[65]
DOPE/CHEMS (2:1) (reverse-phase
evaporation)
pSV2 luc, pRSV luc, pC luc
and pCMV-h-Gal
Transfection of plasmid DNA into
various mammalian cell lines
[86]
DOPE/OA/Chol/DSPE–PEG–MAL
[anti-CD3] (40:20:39.9:0.1)
(hydration method)
pEGlacZ h-Gal condensed with
poly-L-lysine
Transfection of Jurkat T-leukemia cells [82]
Proteins, peptides
DOPE/DOSG/surfactant protein A Superoxide dismutase Respiratory insufficiency [104]
(continued on next page)
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Liposome formulation (composition
and method of preparation)
Encapsulated material Target disease/therapeutic
applications
Reference
DOPE/DOSG (1:1) (hydration method) Prevention of nitric oxide-dependent
motor neuron death induced by
trophic factor withdrawal
[105]
POPE/CHOH/MPL (7:3:0.01)
(freeze– thawing)
V3 peptides Immunomodulating adjuvant system
for the development of HIV and other
viral vaccines
[106]
POPE/CHOH/MPL (7:3:0.01)
(freeze– thawing)
Cytotoxic T lymphocytes (CTL)
epitope peptides from
Hantaan nucleocapsid protein
(M6) or human papilloma
virus E7; FITC-conjugated H-2K
CTL epitope peptide
Tumor therapy mediated by CTL that
recognize tumor-associated antigen
[107]
POPE/CHOH/MPL (7:3:0.01)
(freeze– thawing)
Induction of antigen specific CTL
response in vivo
[108]
Table 2 (continued)
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specificity by targeting the liposomes to cell surface
receptors. For this purpose, different ligands have
been coupled covalently to the liposome surface or
to the distal end of PEG–lipid conjugates. These
include monoclonal antibodies against the H-2Kk
receptor (expressed in several types of tumor cells)
[49], E-selectin (on activated vascular endothelial
cells) [81], CD-19 (on B-lymphoma cells) [57], CD3
(on T-leukemia cells) [82], P-glycoproteins (on endo-
thelial cells) [83] and BCG antigen [16]. pH-sensitive
liposomes targeted to the folate receptor through
coupling of folic acid to the distal end of PEG
molecules have been used recently to deliver neoplas-
tic drugs [65,66] and plasmid DNA [65,84,85].
Under the same experimental conditions, pH-sen-
sitive liposomes have been described to be less
efficient than cationic liposomes to mediate intracel-
lular gene delivery into mammalian cells [86]. Differ-
ent factors, not mutually exclusive, can explain this
difference in transfection activity, including the lower
amount of DNA encapsulated into pH-sensitive lip-
osomes, their lower extent of cell internalization and
the fact that once in the cytoplasm cationic liposomes
could be more efficient in protecting DNA against
nucleases and in mediating its nuclear entry.
Recently, different approaches have been devel-
oped to circumvent the limitations of pH-sensitive
liposomes for nucleic acid delivery. These approaches
share a similar strategy that essentially consists of
complexing preformed pH-sensitive liposomes withplasmid DNA precondensed with a cationic polymer
[64,65,82,84,87]. In comparison with ‘‘conventional’’
liposome formulations, the reported approaches allow
the efficient condensation and protection of plasmid
DNA, and targeting to a specific cell (through cou-
pling of a PEG–lipid conjugate to a ligand), resulting
in improved transfection efficiency. Reddy et al. [87]
were able to further optimize this strategy by promot-
ing nuclear entry of DNA, which was achieved by
incorporation of a nuclear targeting sequence into the
plasmid DNA. Although these approaches generated
satisfactory results in vitro, their pharmacokinetics,
biodistribution and in vivo gene delivery potential
remain to be demonstrated.
The use of liposomes exhibiting both pH-sensitivity
and steric stabilization for nucleic acid delivery has not
been reported extensively. This approach was evaluat-
ed in our laboratory aiming at mediating intracellular
delivery of antisense oligonucleotides and ribozymes
to inhibit virus production in HIV-infected macropha-
ges derived from human peripheral blood monocytes
[44]. As can be observed in Fig. 4, a 15-mer anti-Rev-
responsive element (RRE) phosphorothioate oligo-
nucleotide inhibited viral p24 production by 91%
when delivered by pH-sensitive liposomes, while the
free (unencapsulated) oligonucleotide was not active
against HIV infection in macrophages. The oligonu-
cleotide was also effective when delivered by sterically
stabilized pH-sensitive DOPE/CHEMS/PE–PEG lip-
osomes, but not when encapsulated in non-pH-sensi-
tive liposomes. A non-specific oligonucleotide encap-
Fig. 4. Inhibition of HIV-1 production in human macrophages by free and liposome-encapsulated anti-RRE 15-mer oligonucleotide (ODN) at a
concentration of 3 AM. The viral p24 values are given as the percent of untreated controls (reproduced with permission [44]).
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AM, but at 3 AM it inhibited HIV infection by 53%.
Similar experiments were performed with a 38-mer
chimeric ribozyme complementary to HIV 5V-LTR.
Cationic liposome-mediated delivery of this ribozyme
to HIV-1-infected cells was not effective in reducing
virus production under conditions where the delivery
method was not toxic to the cells [88]. When this
ribozyme was delivered to HIV-infected macrophages
by pH-sensitive liposomes, however, virus production
was inhibited by 88%, while the free ribozyme caused
a decrease of only 10% [44]. As referred to above, the
inclusion of a low mole fraction of PE–PEG in the
membrane of pH-sensitive liposomes (composed of
DOPE/CHEMS) results in prolonged circulation,
without compromising their ability to deliver encap-
sulated molecules into macrophage-like cells [39].
Since these liposomes circulate for prolonged periods
and can localize in lymph nodes after intravenous or
subcutaneous injection [89], they may be useful for
the delivery of antisense molecules to lymph nodes
where active HIV replication takes place [90,91].
As reported previously, other fusogenic liposome
formulations exhibiting long circulation times have
also been applied for nucleic acid delivery. Program-
mable fusogenic vesicles (PFV), previously men-
tioned for the delivery of mitoxantrone, are liposomescomposed of DOPE, Chol, DODAC and an exchange-
able PEG–ceramide conjugate. When incorporating
PEG–ceramide C8 these systems were able to mediate
high in vitro transfection levels of COS-7 and HepG2
cells. High levels of luciferase expression were also
observed upon intraperitoneal administration into B16
intraperitoneal tumor-bearing mice. It is important to
point out that gene expression in tumor tissue was
significantly higher than that observed for cationic
liposome/DNA complexes [60].
PFV have also been evaluated as carriers for the
intracellular delivery of antisense oligonucleotides.
PFV containing PEG–ceramide C14 were shown to
enhance intracellular delivery of oligonucleotides rel-
ative to PFV displaying faster (with PEG–ceramide
C8) or slower (with PEG–ceramide C20) rates of
destabilization. A significant reduction (about 20%
and 25%) in the levels of bcl-2 mRNA was demon-
strated upon treatment of cells with PEG–ceramide
C14 liposomes containing the antisense oligonucleo-
tide against the target proto-oncogene [61].6. Concluding remarks
Soon after liposomes were introduced by Bangham
et al. as models of biological membranes in biophys-
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ically active molecules was recognized due to their
biocompatibility and chemical and structural versatil-
ity. Different applications were envisaged, including
vaccination (as immunological adjuvants), cosmetics,
imaging (carrying contrasting agents) and for the
transport and specific delivery of potent drugs (for
cancer, ophthalmic, pulmonary and infectious dis-
eases), as well as of nucleic acids, aiming at gene
therapy applications. The liposomal delivery of highly
charged or macromolecular drugs into cells presents
the challenge of penetration through the endosomal
membrane. This problem has been resolved partially
by the development of pH-sensitive liposomes, and
sterically stabilized pH-sensitive liposomes. The use
of the latter liposomes, as well as their targeting to
specific tissues, is very likely to facilitate the appli-
cation of ribozymes, antisense oligonucleotides, triple
helix forming oligonucleotides, short interfering
RNAs and other macromolecular drugs to the therapy
of infectious diseases and cancer.Acknowledgements
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